The QualityStocks Daily Wednesday, January 4th, 2023

Today's Top 3 Investment Newsletters

Tiny Gems(VVOS) $1.8800 +154.05%

QualityStocks(VYNE) $0.2379 +73.08%

MarketClub Analysis(CRKN) $0.2964 +60.22%

The QualityStocks Daily Stock List

Vyne Therapeutics (VYNE)

QualityStocks, MarketBeat, The Online Investor and Schaeffer's reported earlier on Vyne Therapeutics (VYNE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Vyne Therapeutics Inc. (NASDAQ: VYNE) is a pharmaceutical firm that is engaged in the development and commercialization of therapeutics for dermatological indications.

The firm has its headquarters in Bridgewater, New Jersey and was incorporated in 2003. Prior to its name change in September 2020, the firm was known as Menlo Therapeutics Inc. It serves consumers around the globe.

The company develops products that’ll help improve the lives of patients with dermatological ailments. It is also working to solve some of today’s most difficult therapeutic challenges by questioning traditional assumptions and finding better solutions to said challenges. It develops its solutions using its Molecule Stabilizing proprietary technology.

The enterprise’s product pipeline comprises of a combination of tofacitinib dubbed FMX114, which is in preclinical trial and has been developed to treat mild-moderate atopic dermatitis; and a topical combination foam known as FCD105, which has concluded phase 2 clinical trials evaluating its effectiveness in treating moderate-severe acne vulgaris. It also develops Zilxi, which is indicated for the treatment of inflammation lesions of papulopustular rosacea in adults. In addition to this, the enterprise develops a topical minocycline dubbed Amzeeq, which is utilized in the treatment of inflammatory lesions of non-nodular acne vulgaris in patients aged 9 and older.

The company recently announced its latest financial results, with its CEO noting that the firm is now fully focused on the development of next-generation therapeutics indicated for the treatment of various immuno-inflammatory ailments. In addition to this, it is focused on creating shareholder value.

Vyne Therapeutics (VYNE), closed Wednesday's trading session at $0.2379, up 73.0811%, on 13,909,172 volume. The average volume for the last 3 months is 75.04M and the stock's 52-week low/high is $0.1107/$1.18.

Crown Electrokinetics (CRKN)

QualityStocks, AwesomeStocks, StockStreetWire, Small Cap Firm, Fierce Analyst, The Stock Dork, StockWireNews and Mega Stock Alerts reported earlier on Crown Electrokinetics (CRKN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Crown ElectroKinetics Corp (NASDAQ: CRKN) is focused on the commercialization of electrokinetic technology.

The firm has its headquarters in Corvallis, Oregon and was incorporated in 2015, on April 20th by Timothy Koch, James Douvikas and Douglas B. Croxall. Prior to its name change in October 2017, the firm was known as 3D Nanocolor Corp. The firm serves consumers in the United States.

The enterprise develops and sells optical switching film which can be applied to the surface of glass or other rigid substrates like acrylic, to control opacity electronically. The film can also be embedded between sheets of smart glass powered by solar strips. The enterprise’s electro kinetic film technology, which is derived from microfluidic and ink technology, uses nanometer-sized particles of pigments which have been charged electrically and suspended in a liquid sandwiched between substrates coated with a transparent conductor oxide film. The film enables transitions between dark and clear, which allows individuals to prevent and/or manage glare, control the tint of the skylight, block out ultraviolet rays, decrease carbon emissions, and decrease the amount of heat entering the home. The enterprise’s offerings can be applied to a range of windows, including automotive sunroofs, residential windows and skylights and commercial buildings.

The company recently entered into an agreement with Hudson Pacific Properties, which involves the installation of energy-saving smart window inserts at some of the properties Hudson owns on the West Coast. This move will not only help Hudson Pacific reduce carbon emissions and energy consumption from cooling and heating systems by at least 25%, but also bring in additional revenue to Crown Electrokinetics and help extend the company’s consumer reach.

Crown Electrokinetics (CRKN), closed Wednesday's trading session at $0.2964, up 60.2162%, on 75,586,780 volume. The average volume for the last 3 months is 12.413M and the stock's 52-week low/high is $0.05/$3.85.

Humanigen Inc. (HGEN)

QualityStocks, MarketBeat, MarketClub Analysis, Trades Of The Day, The Street, Schaeffer's, OTC Stock Review, BUYINS.NET, StreetInsider and InvestorPlace reported earlier on Humanigen Inc. (HGEN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Humanigen Inc. (NASDAQ: HGEN) (FRA: 0KB2) is a biopharmaceutical firm that is focused on the development of immunology monoclonal antibodies and immune-oncology.

The firm has its headquarters in Burlingame, California and was incorporated in 2000, on March 15th by Robert F. Balint and Jeng-Horng Her. Prior to its name change in August 2017, the firm was known as KaloBios Pharmaceuticals Inc. It operates as part of the health sector and serves consumers in the United States.

The company utilizes its proprietary platform technology and biologic capabilities to develop first-in-class human antibody therapies. It is focused on advancing medicines for individuals suffering from rare and neglected diseases and preventing severe and potentially life-threatening side effects linked to chimeric antigen receptor T-cell therapy. The company is party to a clinical collaboration agreement with Kite Pharma Inc. which involves conducting a phase1/2 trial of Lenzilumab.

The enterprise’s product pipeline comprises of an anti-human GM-CSF dubbed Lenzilumab. The antibody formulation has been designed to neutralize human GM-CSF (granulocyte-macrophage colony-stimulating factor antibody) and prevent outcomes associated with the coronavirus. Lenzilumab has also been indicated for the treatment of autoimmune and inflammatory conditions, which include systemic lupus erythematosus, atopic dermatitis, juvenile idiopathic arthritis, inflammatory bowel disease, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis and eosinophilic asthma. In addition to this, the enterprise develops Ifabotuzumab, which has concluded a phase 1 dose escalation portion of a phase 1 clinical trial and is indicated for various hematologic malignancies.

The company is focused on bringing its lenzilumab formulation to patients with the coronavirus. Given that there are currently no treatments for this ailment, the formulation’s success would not only increase investments into the company but also boost its growth.

Humanigen Inc. (HGEN), closed Wednesday's trading session at $0.17, up 41.6667%, on 12,487,036 volume. The average volume for the last 3 months is 8.962M and the stock's 52-week low/high is $0.0924/$4.105.

Elys Game Technology (ELYS)

MarketClub Analysis, RedChip, QualityStocks, Trades Of The Day, MarketBeat, InvestorPlace, Broad Street, TradersPro, The Stock Dork, Daily Trade Alert and BUYINS.NET reported earlier on Elys Game Technology (ELYS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Elys Game Technology Corp. (NASDAQ: ELYS) (FRA: 3UW) is an online sports betting firm that is engaged in the provision of land-based and online gaming services in North America and Europe.

The firm has its headquarters in Toronto, Canada and was incorporated in 1998, on August 26th. Prior to its name change in November 2020, the firm was known as Newgioco Group Inc. It operates as part of the technology sector, in the software and tech services industry, under the software sub-industry and serves consumers across the globe.

The company operates through the Other, Betting platform services and software and Betting establishments segments. The platform services segment is engaged in the delivery of virtual sports products to betting operators while the establishments segment provides leisure betting products to retail consumers directly via betting shop establishments, online distribution on websites or 3rd party agencies that manage land-based retail venues and white-label websites.

The enterprise operates betting platform software services for leisure betting establishments and provides interactive and skilled slots and games, as well as betting products like horse racing, virtual sports betting, bingo, poker, online casino games, sports betting, casino gaming and lottery. It offers its products under the Elys, LovingBet, OriginalBet and NewAleabet trade names; mobile devices under the Newgioco brand name; its website; and land-based retail and physical locations.

The firm recently entered into a definitive purchase agreement to acquire Bookmakers Company LLC. This move provides Elys’ shareholders with a good growth opportunity, which will combine the latter’s expertise in bookmaking and Elys’ leading-edge betting technology. This is in addition to extending Elys’ consumer reach, which will be good for the company’s growth.

Elys Game Technology (ELYS), closed Wednesday's trading session at $0.3604, up 39.9612%, on 8,962,272 volume. The average volume for the last 3 months is 752,065 and the stock's 52-week low/high is $0.111/$3.4711.

Aslan Pharmaceuticals (ASLN)

TradersPro, StockMarketWatch, QualityStocks, MarketBeat, BUYINS.NET, Schaeffer's, MarketClub Analysis and InvestorsUnderground reported earlier on Aslan Pharmaceuticals (ASLN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aslan Pharmaceuticals Limited (NASDAQ: ASLN) (FRA: 7A9) is a clinical-stage biopharmaceutical firm focused on immunology, which is centered on the development of treatments of novel therapies.

The firm has its headquarters in Singapore and was incorporated in 2010 by Jeffrey Tomlinson, Mark McHale and Carl Aslan Jason Morton Firth. It operates in the health care sector under the biotech and pharma sub-industry. The firm targets ailments that are prevalent in Asia and orphan indications in Europe and the United States.

The company is party to a joint venture with Bukwang Pharmaceutical Co. Ltd, which entails the development of immune-oncology therapeutics that target the AhR pathway. It also has partners, which include CSL Limited, Array BioPharma and Almirall, and is focused on developing therapies that transform the lives of patients.

The enterprise’s pipeline is made up of a first-in-class monoclonal therapy dubbed ASLAN004 which is indicated for the treatment of atopic dermatitis and asthma, among other immunology indications. Atopic dermatitis, commonly known as eczema, makes an individual’s skin itchy and red. On the other hand, asthma causes a patient’s airways to swell and narrow, which makes it harder to breathe and results in coughing or wheezing. In addition to this, it also develops a small-molecule dihydroorotate dehydrogenase inhibitor known as ASLAN003, indicated for the treatment of various autoimmune conditions. Furthermore, the enterprise also produces an AhR antagonist and varlitinib.

The company’s ASLAN004 formulation, which recently concluded its phase 1 study and is set to proceed to phase 2, has shown remarkable effectiveness and safety. Its success will benefit patients with atopic dermatitis and bring in more investors into the firm, which will be good for the company’s growth.

Aslan Pharmaceuticals (ASLN), closed Wednesday's trading session at $0.5984, up 37.5158%, on 752,065 volume. The average volume for the last 3 months is 2,170 and the stock's 52-week low/high is $0.3405/$1.23.

PropertyGuru Group (PGRU)

MarketBeat reported earlier on PropertyGuru Group (PGRU), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

PropertyGuru Group Limited (NYSE: PGRU) is a property technology firm that provides online real estate services.

The firm has its headquarters in Singapore and was incorporated in 2007 by Jani Rautiainen and Stephen Nicholas Melhuish. It operates as part of the real estate services industry, under the real estate sector. The enterprise serves consumers around the globe.

The company’s digital property classifieds marketplaces provide agents, developers and property seekers access to real estate data and online tools to help them with their property goals throughout their property transaction journey. It operates across Singapore, Thailand, Malaysia, Vietnam and Indonesia, through its online property database

The enterprise's portfolio of property portals comprises of PropertyGuru FastKey, mortgage marketplace PropertyGuru Finance, and other property offerings, including awards, events and publications across Asia. PropertyGuru DataSense offers data solutions and market intelligence to estimate the list price and evaluate home equity online through its tools. PropertyGuru FastKey is a software as a Service (SaaS) platform that helps real estate developers enhance their sales processes. It automates the full project sales cycle from launch to close of sale. It also provides various marketing and content solutions. The enterprise serves agents and developers to advertise commercial and residential properties for sale or rent to property seekers.

The firm, which recently announced its latest financial results, remains focused on expanding its value proposition and investing in innovation. This will help create value for its shareholders while also bolstering the firm’s overall growth.

PropertyGuru Group (PGRU), closed Wednesday's trading session at $4.58, up 4.0909%, on 2,170 volume. The average volume for the last 3 months is 2.759M and the stock's 52-week low/high is $4.03/$9.00.

EVgo Inc (EVGO)

MarketClub Analysis, Schaeffer's, MarketBeat, InvestorPlace, Zacks, Trades Of The Day, The Street, The Online Investor and QualityStocks reported earlier on EVgo Inc (EVGO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

EVgo Inc. (NASDAQ: EVGO) is a company focused on operating and owning a direct current fast charging network.

The firm has its headquarters in Los Angeles, California and was incorporated in 2010. It operates as part of the specialty retail industry, under the consumer cyclical sector. The firm serves consumers in the United States.

The company, also known as EVgo Holdco, EVgo Services, offers the EVgo network, which is powered by renewable electricity using renewable energy certificates (RECs). Its fast chargers are compatible with all electric car models currently on the market that accept direct current (DC) Fast Charging.

The enterprise provides electricity directly to drivers, who access its publicly available networked chargers; original equipment manufacturer charging and related services; charging as a service and fleet dedicated charging services; and fleet and rideshare public charging services. Its fast chargers deliver convenient, fast charges of up to 90 miles of range in 30 minutes. The enterprise also offers ancillary services, which include customization of digital applications, loyalty programs, charging data integration, access to chargers behind parking lot or garage, pay gates and pilots microtargeted advertising, and charging reservations; and maintenance and development and project management services through eXtendTM, including electric vehicle supply equipment installation, networking, and operations.

The firm recently entered into a partnership with Lyft, which will accelerate rideshare electrification in the U.S. This will extend the firm’s reach while also generating additional revenues and encouraging more investments into the firm.

EVgo Inc (EVGO), closed Wednesday's trading session at $3.98, off by 3.163%, on 2,785,017 volume. The average volume for the last 3 months is 1.23M and the stock's 52-week low/high is $3.65/$14.23.

Genius Sports (GENI)

MarketBeat, Schaeffer's, InvestorPlace, Wealth Insider Alert, Trades Of The Day and MarketClub Analysis reported earlier on Genius Sports (GENI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Genius Sports Ltd (NYSE: GENI) is a company focused on the development and sale of technology-led products and services to the sports betting, sports and sports media industries.

The firm has its headquarters in London, the United Kingdom and was incorporated in 2016. It operates as part of the internet content and information industry, under the communication services sector. The firm serves consumers around the globe, with a focus on those in Europe.

The company’s services are organized into 3 key products areas; Sports Technology and Services; Media Technology, Content and Services; and Betting Technology, Content and Services. All of its products are powered by proprietary technology and robust data infrastructure. The company generates the majority of its revenue from the Betting Technology, Content and Services division. Geographically, it generates most of its revenue from Europe.

The enterprise provides technology infrastructure for the collection, integration, and distribution of live data of sports leagues; end-to-end integrity services to sports leagues, such as full-time active monitoring technology; streaming solutions including technology, automatic production, and distribution for sports to commercialize video footage of their games; and a full suite of offline and online educational and consultancy services. It also offers pre-game and in-game odds feeds; live sports data collection; risk management services; and live streaming services, among others.

The company was recently awarded a supplier license by Ohio Sports Gaming, which will allow it to offer its products and services to fans in the state. This move will generate additional revenue for the company while also creating value for its shareholders.

Genius Sports (GENI), closed Wednesday's trading session at $3.47, up 2.3599%, on 1,238,529 volume. The average volume for the last 3 months is 164,504 and the stock's 52-week low/high is $2.20/$7.92.

Brilliant Earth Group (BRLT)

Schaeffer's, StocksEarning, MarketClub Analysis and MarketBeat reported earlier on Brilliant Earth Group (BRLT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Brilliant Earth Group Inc. (NASDAQ: BRLT) is a jewelry firm that is focused on designing, procuring and retail selling ethically-sourced diamonds, gemstones and jewelry.

The firm has its headquarters in San Francisco, California and was incorporated in 2005 by Eric Grossberg and Beth Gerstein. It operates as part of the luxury goods industry, under the consumer cyclical sector. The firm’s co-headquarters are located in Denver, Colorado. It serves consumers across the globe.

The company’s sales primarily comprise of revenue from diamond, gemstone and jewelry retail sales. It sells its products in the United States and other international countries. It generates the majority of its revenue from the U.S.

The enterprise’s product assortment and merchandise include a collection of natural and lab-grown diamond engagement rings, which are made-to-order through its Create Your Own ring digital tool. It also offers gemstone rings, wedding and anniversary rings, and fine jewelry like necklaces, bracelets and earrings. It sells directly to consumers through its omnichannel sales platform, including e-commerce and showrooms. As of November 2022, it had 25 showrooms located in San Francisco, Los Angeles, Boston, Chicago, San Diego, Washington D.C., Denver, Philadelphia, Atlanta, Seattle, Portland, Austin, Dallas, New York, and Scottsdale.

The firm, which remains focused on strengthening its physical presence, recently launched its first showroom in Santa Monica and an additional one in California. This move will not only extend its consumer reach but will also generate additional revenues for the firm, while also generating value for its shareholders.

Brilliant Earth Group (BRLT), closed Wednesday's trading session at $4.21, up 3.9506%, on 164,554 volume. The average volume for the last 3 months is 3.769M and the stock's 52-week low/high is $3.60/$18.76.

Ballard Power Systems (BLDP)

MarketClub Analysis, SmarTrend Newsletters, MarketBeat, StreetInsider, InvestorPlace, Investopedia, The Street, BUYINS.NET, Wall Street Resources, Zacks, Schaeffer's, PennyStocks24, StreetAuthority Financial, StockMarketWatch, TopStockAnalysts, ProfitableTrading, Energy and Capital, Greenbackers, Money Morning, TraderPower, Wyatt Investment Research, Trades Of The Day, CRWEFinance, StockEgg, MonsterStocksPicks, PennyOmega, PennyToBuck, BullRally, PennyInvest,, Insider Wealth Alert, Investors Alley, CRWEWallStreet, CoolPennyStocks, HotOTC, DrStockPick, Dividend Opportunities, Daily Trade Alert, MadPennyStocks, StockHotTips, PennyStockVille, StockRich, Hit and Run Candle Sticks, PennyTrader Publisher, Early Bird, Trade of the Week, StreetAuthority Daily, InvestorsUnderground, Street Insider, Stockgoodies, Trading Markets, Barchart, Stock Stars, CRWEPicks, YOLOTraderAlerts, BestOtc, Alternative Energy, InvestorGuide, Wall Street Mover, Wealth Insider Alert, Clutch Investments, TradersPro, WealthMakers, Top Pros' Top Picks, Todd Horwitz, Uncommon Wisdom, OTCPicks, Rick Saddler, SmallCapVoice, Agora Financial, Stock Beast, Stock News Now, Pennybuster, The Online Investor, Penny Invest, Today's Financial News, Stocks That Move, Market Authority, SuperNova Elite, QualityStocks, Investor Ideas, Investing Futures, The Stock Enthusiast and Penny Stock Rumble reported earlier on Ballard Power Systems (BLDP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ballard Power Systems Inc. (NASDAQ: BLDP) is a company focused on designing, developing, manufacturing, selling and servicing proton exchange membrane (PEM) fuel cell products.

The firm has its headquarters in Burnaby, Canada and was incorporated in 1979. It operates as part of the specialty industrial machinery industry, under the industrials sector. The firm serves consumers around the globe.

The company operates through the Power generation, Automotive and Material products segments. It is party to a strategic alliance with Linamar Corp, which entails the co-development and sale of fuel cell power-trains and components for class 1 and 2 vehicles in Europe and North America. The company’s sales are mainly concentrated in Europe, the United States and China.

The enterprise’s fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. It provides its products for power product markets, comprising of heavy-duty motives for truck, rail, bus and marine applications; material handling; and backup power. It also offers technology solutions, including engineering and technology transfer, as well as licenses and sells its intellectual property portfolio and fundamental knowledge for a range of PEM fuel cell applications. This is in addition to offering hydrogen fuel cell powertrain and vehicle systems integration solutions.

The company recently entered into a purchase agreement for fuel cell engines with Amogy Inc. This move will not only generate additional revenues for the company but also help extend its consumer reach, which will be good for its growth.

Ballard Power Systems (BLDP), closed Wednesday's trading session at $5.17, up 9.3023%, on 3,768,935 volume. The average volume for the last 3 months is 62.853M and the stock's 52-week low/high is $4.43/$12.71.

NIO Inc. (NIO)

Green Car Stocks, InvestorPlace, Schaeffer's, The Street, MarketClub Analysis, MarketBeat, Daily Trade Alert, Trades Of The Day, StocksEarning, Kiplinger Today, The Online Investor, QualityStocks, Zacks, StreetInsider, StockMarketWatch, INO Market Report, BUYINS.NET, Early Bird, Cabot Wealth, Wealth Insider Alert, The Wealth Report, CNBC Breaking News, InvestorsUnderground, Investopedia, Daily Wealth, TradersPro, wyatt research newsletter, Energy and Capital, Investors Alley, CRWEWallStreet, FreeRealTime, Jim Cramer, Wealth Daily, InvestorsObserver Team, AllPennyStocks, MarketClub, TopPennyStockMovers, Top Pros' Top Picks, Stock Market Watch and InvestorIntel reported earlier on NIO Inc. (NIO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Electric vehicles are positioned for a killer new year in 2023 since many countries, with the exception of China, have already seen a decline in COVID-19, and the world is settling into the fact that there is a war in Ukraine. The following three forecasts point to significant events in this new year.

Tesla FSD Could Become Widely Available

Throughout its innovation, the full self-driving (FSD) feature for Tesla has generated a great deal of controversy. In 2019, Elon Musk even stated that a million robotaxis would hit the road in the year 2020, which was not the case; two years later nothing of the sort has happened. In addition, multiple lawsuits have been filed over the failure of FSD. A law has even been passed in California regarding self-driving vehicles.

However, the introduction of the Dojo supercomputer may represent a significant step forward. In the end, this will result in a significant change in the capabilities of Tesla’s FSD. The 160,000 available beta testers will be responsible for providing raw data to these models, which will then be processed by the supercomputers. Therefore, assuming that laws do not impede progress, the year 2023 might be the year when self-driving technology finally leaves the beta stage and enters the mass market.

The $25K Tesla Won’t Show Up Yet

Tesla has temporarily halted the development of its $25K model in order to concentrate on global distribution of its current models. At the moment, it has a lot on its plate before switching to a new model type because both the Model Y and the Model 3 are doing exceptionally well in the market. Furthermore, the ongoing problems with the supply network of car components make this a difficult time for the auto industry.

Due to unfortunate occurrences such as the pandemic and the war in Ukraine, affordable electric vehicles are unlikely to be on the market by 2023. Rechargeable battery cell prices in 2020 suggested that electric cars would become competitively priced with comparable petroleum vehicles in 2023 or 2024.

It is improbable that this will happen right away. But given the coming completion of large gigafactories for batteries and the anticipated sharp increase in supply in the coming years (2025 or 2026), it still might be on the horizon. The $25K Tesla will not have been canceled; it has only been delayed, just like the mainstream of cheap electric vehicles.

The Coming of China and Others

Tesla has long dominated the electric vehicle space, but this won’t be the case in the future given the rise of Chinese auto companies such as NIO Inc. (NYSE: NIO) and South Korean manufacturers that are attempting to increase their market share for electric vehicles. The formerly British and currently Chinese brand MG hopes that its MG4 game-changer, along with other fantastic electric vehicles, will revolutionize the automotive industry. The Niro EV, Soul EV and EV6 from Kia, as well as the Hyundai Kona Electric and IONIQ 5 from the Korean Hyundai Motor Group, will serve as a crucial beachhead into Europe. However, many more products are being introduced in 2023, including the even more innovative IONIQ 7.

NIO Inc. (NIO), closed Wednesday's trading session at $10.63, up 10.3842%, on 63,723,786 volume. The average volume for the last 3 months is 715,356 and the stock's 52-week low/high is $8.375/$33.39.

Warrior Met Coal Inc. (HCC)

The Online Investor, MarketBeat, StreetInsider, Market Report, QualityStocks, Zacks, The Street, Trades Of The Day, Daily Trade Alert, BUYINS.NET, StockMarketWatch, InvestorPlace, MarketClub Analysis, Schaeffer's, StreetAuthority Daily, AllPennyStocks, Market Intelligence Center Alert, Street Insider, CRWEFinance, TopStockAnalysts and SmarTrend Newsletters reported earlier on Warrior Met Coal Inc. (HCC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

New data shows that reverting back to the use of coal to generate power in some regions in Europe has not led to an increase in greenhouse emissions. Some European Union member states, including Poland and Germany, have returned to using coal to generate power in the short-term, in the face of supply constraints and exorbitant gas prices that have followed Ukraine’s invasion by Russia earlier last year.

The data, released by the Center for Research on Energy and Clean Air, shows that greenhouse gas emissions in the EU were at their lowest in at least three decades last month.

An analysis conducted by the center also shows that only a small portion of November’s drop in the use of fossil fuels could be attributed to the harsh weather. The analysts stated that in the power sector, mild temperatures made up 2% of the 12% decrease in fossil fuel demand. They explained that outside the power sector, milder temperatures accounted for a 6% decrease in the demand for gas, which is low in comparison to the total decrease in demand for fossil fuels, which stood at 26%.

While it is expected that low temperatures this month will cause more coal to be burned, making it harder to meet targets to reduce the consumption of fossil fuels, this may not be the case. Lead analyst Lauri Myllyvirta explained that the data demonstrated that allegations against the European Union’s failure to honor climate targets were wrong. Myllyvirta argued that the perception that the EU was falling back on its commitments as a result of the Ukraine war were wrong because coal consumption was still low.

Last month, the European Union used less coal than it had in November 2021 and less than in the same month for the past 30 years. This is despite the substantial decrease in output from nuclear reactors in France and Germany, which saw France decrease its power demand significantly and Germany make up for the deficit by increasing power generation from renewable sources such as solar and wind. The data also shows that Poland and Germany used less coal than they had in 2021, with Finland’s use of coal increasing only slightly.

It should be noted though that coal usage is dependent on the weather. If temperatures drop, more gas may be burnt, which may stall progress on reducing the use of fossil fuels this cold season.

As the cold intensifies, coal extractors such as Warrior Met Coal Inc. (NYSE: HCC) are likely to see an uptick in demand, enabling them to offer greater value to their shareholders.

Warrior Met Coal Inc. (HCC), closed Wednesday's trading session at $32.99, up 2.7406%, on 736,605 volume. The average volume for the last 3 months is 66,025 and the stock's 52-week low/high is $24.72/$42.95.

The QualityStocks Company Corner

SideChannel Inc. (OTCQB: SDCH)

The QualityStocks Daily Newsletter would like to spotlight SideChannel Inc. (OTCQB: SDCH).

Companies that experience data breaches face, on average, $4.35million in consequential costs, demonstrating the importance of aneffective cybersecurity response

Small to medium-sized businesses (“SMBs”) generally find the costsof hiring full-time cybersecurity experts to be prohibitive, makingit difficult for them to effectively protect themselves frompotential cyber crimes

Virtual chief information security officer (“vCISO”) services arefilling the breach with expert cybersecurity consultancy providedon a contract basis that is far more affordable than a full-timehire

Cybersecurity services and technology provider SideChannel Inc.provides vCISO consultancy as well as proprietary Enclave softwarethat addresses access control needs through microsegmentation

SideChannel recently reported that its solutions have resulted in71 percent YOY revenue growth with vCISO-specific services rising93 percent and recurring software & services growing 367percent

The industry providing virtual chief information security officer(“vCISO”) services is positioned to grow, given that cybercrime isone of the fastest-growing crimes in the United States and that theaverage cost of a data breach is $4.35 million, but the cost ofhiring a full-time staff CISO can itself run into the hundreds ofthousands of dollars, a recent Forbes report notes (’s (OTCQB: SDCH) CEO and Founder Brian Haugli was featured in a recent podcastproduced by Hacker Valley Studio. The discussion centers around strategy and leadership incybersecurity, with Haugli sharing what he has learned about apurposeful approach. “Strategy is not technology, it’s figuring outwhat you want to look like when you grow up, in a sense,” Hauglisaid, discussing his philosophy and the tenants in creating astrong security strategy. “Everyone jumps to the shiny object. Whatcan I buy to go solve this problem? You never stop and question:Was that the first problem I was supposed to solve? … I think a lotof people throw strategy around as a grander concept and don'tactually think about the elements that need to go into buildingone. You need to align to a definition that supports your businessand outcomes, and that’s what is strategic.”

To view the full article, visit

SideChannel Inc. (OTCQB: SDCH) simplifies cybersecurity for mid-market companies by matching them with highly experienced information security officers at a cost lower than building an in-house information security team or hiring a full-time CISO.

SideChannel’s team of virtual Chief Information Security Officers (vCISOs) possesses a combined 400-plus years of experience in cybersecurity. They’ve honed their skills and abilities in places like Anthem, Dick’s Sporting Goods, Best Buy, TD Bank and the Pentagon. SideChannel lends this talent to clients, creating value in the form of a bespoke cybersecurity program perfectly sized for the growing enterprise.

SideChannel is committed to creating top-tier cybersecurity programs for SMBs to help them protect their data and assets. To date, SideChannel has created more than 50 multi-layered cybersecurity programs for its clients.


Reports show that cyberattacks on SMBs have increased in recent years, as organizations’ network attack surfaces have grown exponentially with remote and in-office workers increasingly relying on cloud environments, mobile devices, software applications and third-party suppliers to conduct business.

SideChannel continues expanding its service offerings, workforce and customer base, attracting over 20 virtual CISOs to serve across industries including fintech, biotech, healthcare, manufacturing, legal, defense and technology services. The company is based in Worcester, Massachusetts.

Market Opportunity

An analysis from ReportLinker states that the global cybersecurity market is expected to grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving cyber security market growth, according to the report.

A lack of cybersecurity professionals and the budget constraints among SMBs and start-ups in developing economies are expected to hinder market growth. Cybercriminals are using automated techniques to attack SMBs’ networks to take advantage of their weak security infrastructures. To save money, time and resources, SMBs are seeking cybersecurity solutions.


Enclave expands upon SideChannel’s cybersecurity service offerings by solving a pervasive network security problem with a simple tool.

A comprehensive cloud and network security solution, Enclave enables IT teams to contain breaches faster, reduce network outages, minimize latency and strengthen overall security defense.

Enclave creates the foundation for a Zero Trust network security model IT can build upon.

With Enclave, IT can easily segment their company’s network, organize personnel and computing devices at the employee workload level, and implement security controls across all network segments.

Enclave was designed and purpose built to serve the growing security needs of SMBs, a traditionally underserved market that is more prone to cyberattacks but has limited protection due to smaller budgets, inadequate IT security staffing and a lack of cybersecurity awareness among top executives.

Enclave is an affordable and effective network security solution that shrinks the attack surface area exposed to a cyber intruder and significantly reduces the amount of effort required to operate securely.

Management Team

Brian Haugli is CEO of SideChannel. He has led programs for the U.S. Department of Defense, the Pentagon, and Fortune 500 companies. He is an expert on National Institute of Standards and Technology guidance, threat intelligence implementations and strategic organizational initiatives. He is a professor at Boston College, Woods College of Advancing Studies Master’s Program in Cybersecurity. He is also a contributing author for the Wiley book ‘Cybersecurity Risk Management’.

Ryan Polk is CFO at SideChannel. He has been the principal of Perissos Partners, an executive consulting firm, since June 2017. He also served in executive roles in the portfolio companies owned by Lacy Diversified, with combined revenue approaching $2 billion. He served as the Vice President for Corporate Financial Planning and Analysis for Brightpoint, a publicly traded, Fortune 500 mobile device logistics company. He earned a bachelor’s degree in accounting and industrial management from Purdue University.

Nicholas Hnatiw is Chief Technology Officer at SideChannel. Prior to joining the company, he served as the technical director for network operations supporting U.S. Cyber Command, U.S. Intelligence Agencies and other Department of Defense research organizations. He was also the CEO of Loki Labs, a cyber security firm. He earned a bachelor’s degree in computer engineering and computer science at the University of Massachusetts, Amherst.

Bill Roberts is SideChannel’s CISO. He most recently served as the vice president, IS & CISO for Hologic Inc., a global medical device company, where he established cyber security and IT compliance programs. Prior to Hologic, he was vice president of information security for Cytyc Corporation, which was acquired by Hologic in 2007. At Cytyc, he managed global IT as the company grew from 140 employees to 1,500 and from $40 million in revenue to over $750 million.

SideChannel Inc. (OTCQB: SDCH), closed Wednesday's trading session at $0.107811, up 7.811%, on 66,025 volume. The average volume for the last 3 months is 610,129 and the stock's 52-week low/high is $0.06/$0.18.

Recent News

Vision Energy Corp. (OTCQB: VENG)

The QualityStocks Daily Newsletter would like to spotlight Vision Energy Corp. (OTCQB: VENG).

Vision Energy (OTCQB: VENG) recently entered into a corporation agreement with LindeEngineering to accelerate efforts for the company’s pioneeringGreen Energy Terminal in the North Sea Port of Vlissingen, theNetherlands. “Linde Engineering, a leading global industrial gasesand engineering company with 2021 sales of $31 billion, willdeliver preliminary Front-End Engineering and Design (‘FEED’)services to the project including design and engineering of 150,000cubic meters (‘CBM’) of green ammonia (‘NH3’) storage, truck andbarge loading facilities, ship loading and unloading facilities, aswell as utilities, infrastructure and buildings… Vision Energy isin the advanced stages of planning the construction and delivery ofNorthwestern Europe’s first import, storage and handling terminaldesigned exclusively for hydrogen carriers, renewable energyproducts and low-carbon fuels. Total capacity under phase 1 is forup to 400,000 CBM including 150,000 CBM allocated to green ammonia,180,000 CBM allocated to renewable methanol and 70,000 CBMallocated to biofuels,” a recent article reads. “Our Green EnergyTerminal Project will accelerate and advance the energy transitionand facilitate Northwestern Europe’s ambition to achieve Net Zerothrough carbon abatement and adoption of hydrogen as a corefeedstock and fuel,” Vision Energy CEO Andrew Hromyk is quoted assaying. To view the full article, visit

Vision Energy Corp. (OTCQB: VENG) (“Vision Energy”) is a forward-looking energy company developing carbon reduced solutions for the commercial, industrial and transportation sectors. Vision Energy is leveraging its team’s proven track-record in site and asset procurement, accelerating development and permitting processes, plant design, and grid integration to facilitate low-carbon energy production, supply and distribution. The company is pursuing reliable offtake relationships and operating partnerships with energy industry participants and end users seeking carbon abatements across feedstock and fuels. Vision Energy is committed to providing low carbon energy solutions with maximized yield, with projects designed to exploit existing gas and power infrastructure, to integrate and facilitate import and/or distribution of reduced-carbon energy to domestic and global supply chains.

The company believes that hydrogen and liquid carriers of hydrogen are the most reliable alternatives to fossil fuels. Hydrogen is anticipated by many energy analysts to become more widely competitive as an alternative mobile energy source as early as 2030, as economies of scale drive down costs.

According to the International Energy Agency report ‘Hydrogen in North-Western Europe (2021)’, the region is well placed to lead hydrogen adoption as a clean energy source. Today, this region comprises approximately 5% of global hydrogen demand and 60% of European demand. Moreover, the region is home to the largest industrial ports in Europe, where much of this hydrogen demand is located, and presents a well-developed natural gas infrastructure connecting these ports with other industrial hubs. This gas network could be partially repurposed to facilitate hydrogen delivery from production sites to demand centers. Governments in this region also have ambitious goals for greenhouse gas emissions reduction and there is strong political interest in hydrogen as a pathway to maintaining industrial activity in the region.

Vision Energy is based in Jersey City, New Jersey.


Through wholly owned subsidiary Evolution Terminals BV, Vision Energy is pioneering a Green Energy Hub development project for the import, storage and distribution of low-carbon renewable fuels and hydrogen carriers, strategically located in the North Sea port of Vlissingen at the mouth of the Westerschelde estuary in the Netherlands. This Green Energy Hub is positioned to be the first terminal in Europe focused on green and low-carbon energy products.

Vision Energy is at an advanced stage of planning for the construction of its Green Energy Hub and is on schedule to file for the remaining construction and environmental permits by December 2022. The Green Energy Hub design is capable of receiving seagoing vessels, barges and coasters, served by a dedicated deep-water jetty as well as rail and truck loading infrastructure that will enable direct access to purpose-built storage and handling facilities for low-carbon fuels and hydrogen carriers, including ammonia, methanol and liquid organics. Phase 1 capital expense is estimated at approximately €450 million, including jetty infrastructure, and will provide for up to 400,000 cubic meters (CBM) of storage capacity with land already secured for future expansion.

Market Opportunity

In Northwestern Europe, the market for green hydrogen, or hydrogen produced by renewable energy, is growing rapidly. The current hydrogen demand projections outstrip the scheduled production for the next five to 10 years.

The company believes that all producers will face high demand. Moving beyond its initial Green Energy Hub, Vision Energy is focused on countries where governments support a regulatory standard that promotes hydrogen production and consumption. Many governments have established various incentives and financial mechanisms to accelerate and promote the use of hydrogen as a renewable energy source.

The EU, through its European Green Deal, has set an objective to become climate-neutral by 2050, implying the near total phase-out of fossil fuels in the EU energy system, and many countries are working to put in place subsidy programs for the development of green hydrogen facilities in anticipation of this goal.

Vision Energy projects its total addressable market at €10 billion by 2050.

Management Team

Andrew Hromyk is CEO of Vision Energy. He has supported and operated chemical and energy operations in the Permian Basin, central and south Texas, Arkansas, Alberta and internationally. An active investor, he has been involved with companies developing a diverse range of technologies, from enhanced and conventional hydrocarbon recovery processes to wireless infrastructure. He has participated in numerous industrial and commercial real estate developments. He also has served as a director of several private companies that became publicly traded on Nasdaq, NYSE and TSX. He studied economics at Chaminade University and the University of British Columbia.

Arron Smyth is Executive Vice President of Corporate Development at Vision Energy. He has more than 18 years of experience in financial services, investment banking, business leadership and operations in both developed and emerging markets. Since 2018, he has been Managing Director Europe for the First Finance group of companies, developing and supporting the group’s private equity investments and projects, including Evolution Terminals, the Netherlands-based developer of tank terminal and port infrastructure for the bulk storage and handling of clean and sustainable energy products.

Matthew Hidalgo is CFO of Vision Energy. He has over 15 years of experience in accounting, operations, finance, corporate restructuring and integrating acquisitions. He is a Managing Partner at Turquino Equity LLC, a private equity investment firm. Formerly, he was the controller and operations manager for the largest subsidiary of WPCS International Incorporated. Prior roles included managing accounting functions for several Australian subsidiaries. After graduating from Penn State with a bachelor’s degree in accounting, he began his career at PricewaterhouseCoopers.

Vision Energy Corp. (OTCQB: VENG), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

The 36-person human pharmacokinetic randomized, double-blind,cross-over study NIC-H22-1 will compare its patentedDehydraTECH(TM)-nicotine to leading nicotine pouches On! and Zyn

The white pouch oral delivery of nicotine is thought to avoidharmful lung outcomes that smokers and vapers experience

The global nicotine pouch market was valued at $2.33 billion in2020 and is expected to reach $21.84 billion by 2027, driven by anincrease in the number of consumers seeking alternative forms ofnicotine that do not involve lung exposure

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, announced thatdosing has commenced for its human clinical nicotine studyNIC-H22-1. The study is a 36-person human pharmacokineticrandomized, double-blind, cross-over study conducted on currentcigarette smoking subjects. Each participant will visit thelaboratory and be dosed three times over the coming weeks. Only oneoral nicotine pouch will be administered and evaluated during eachvisit. Participants will either receive Lexaria’s patentedDehydraTECH(TM)-nicotine, On! brand manufactured by Altria, or Zynbrand manufactured by Swedish Match during that time (

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Wednesday's trading session at $2.7001, up 5.8863%, on 7,041 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.80/$4.94.

Recent News

MetAlert Inc. (OTC: MLRT)

The QualityStocks Daily Newsletter would like to spotlight MetAlert Inc. (OTC: MLRT).

MetAlert has, since its inception, sought to offer quality-of-lifeimprovements to patients and caregivers dealing with Alzheimer’s,dementia, and autism (“ADA”)

This focus has led to the company offering products and serviceswithin the GPS/BLE wearable technology, personal location,wandering assistive technology, and health data collection andmonitoring

Also important is MetAlert’s offering of hearing aids, ranging fromits flagship Hear IQ 4 rechargeable, app-controlled hearing aid,the NRBz noise-reducing buds, HearingVite, and the Ear-Ring Reliefformula

MetAlert understands the correlation between cognitive decline andhearing loss, with persons with hearing loss who wore devicesperforming better on cognitive scores in the short term, accordingto a study published on December 5, 2022

The company is optimistic that, as the conversation around ADAprogresses, more people will start seeking early diagnosis andtreatment for cognitive decline and embrace the use of hearing aidsas one step to preserve cognition

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices andwearable technology products, has, since its inception, sought tooffer quality of life improvements to patients and consumers whohave Alzheimer’s, dementia and autism (“ADA”). This focus hasyielded the design, development, manufacturing, distribution, andsale of products and services within the GPS/BLE wearabletechnology, personal location, wandering assistive technology, andhealth data collection and monitoring. All these offerings havebeen well-received and have proven to offer value to thoseafflicted with ADA.

MetAlert Inc. (OTC: MLRT) is a pioneer in location sensitive health monitoring devices (estimated $47 billion industry in 2021) and wearable technology products (industry forecast to reach $174 billion by 2030).

With over 20 years of experience and an extensive patent portfolio (30+), MetAlert is a leader for consumers/patients afflicted with Alzheimer’s, dementia, and autism (ADA). This market represents approximately 2.9% of the world’s population (approximately 34 million people in 24 developed countries). Due to specific behaviors (problems with memory, adversity to wearing unknown items, etc.) of consumers/patients in this market segment, traditional products, such as an iPhone or Fitbit, are not a practical solution. This has created a significant market with very few competitors for MetAlert.

MetAlert and its subsidiaries are engaged in designing, developing, manufacturing, distributing, and selling products and services in GPS/BLE wearable technology, personal location, wandering assistive technology, and health data collection and monitoring. The company offers a global end-to-end hardware, software, and connectivity solution, in addition to developing two-way tracking technologies, which seamlessly integrate with consumer products and enterprise applications.

Using its award-winning, patented GPS SmartSole® as a hub for collecting and transmitting data to the cloud in real-time, MetAlert is expanding its value proposition to consumers and increasing its revenue per user (RPU) while creating the largest database of health statistics for ADA consumers/patients. MetAlert generates revenue from product sales, recurring subscriptions, intellectual property (IP) licensing, and professional services. The company has international distributors servicing customers in over 35 countries and is an approved U.S. military government contractor. Its customers include public health authorities and municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes and consumers.

The company is headquartered in Los Angeles, California, with a sales office in London, England, and distributors across the globe.


  • GPS SmartSoles® HUB (launched Q4 2022) is a GPS/BLE-equipped insole that allows remote monitoring, data collection, and encrypted data transmission to the cloud.
    • Telehealth (available Q4 2022) allows access remotely to doctors and other health professionals on an as-needed basis. This service will also function as the prescribing doctor once Medicare reimbursement codes are established.
    • Concierge (available Q4 2022) provides 24/7/365 enhanced emergency response that coordinates with all relevant parties to quickly detect false alarms and escalate response as needed.
    • Bluetooth Enabled Devices (available Q1 2023) include third-party devices that collect vitals and other health data and connect with the GPS Smartsoles® HUB.
    • Artificial Intelligence (available Q1 2023) software will evaluate the Teradata of health information identifying trends and respond to preestablished alert thresholds.
  • Take-Along Tracker is a small GPS tracking device – less than three inches long – that works with 4G cellular service and will have the same “HUB” functionality as the GPS Smartsoles®. This versatile and affordable mini tracker boasts super long battery life, with up to 14 days of operation per charge.
  • RoomMate™ is a wall-mounted alert system that detects and alerts caregivers about patient behavior that could lead to falls and injuries. The system features 3D infrared and wall-mounted sensors, eliminating the need for any other physical installation or wearables. RoomMate™ offers patient privacy by design. Images are not stored, but all actions are logged. It’s a unique solution for looking after patients without intruding on their personal space.

Market Outlook

According to Grand View Research (Patient Monitoring Devices Market Size & Share Report, 2030), the global patient monitoring devices market size was valued at $47.0 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 7.8% from 2022 to 2030. The expansion of the industry can be attributed to the rise in demand for monitoring devices used to measure, distribute, record, and display a variety of biometric data, including blood pressure, temperature, and blood oxygen saturation level.

The growing number of chronic disorders, such as diabetes, stroke, and kidney disease, are driving the demand for patient monitoring devices. For instance, according to the World Health Organization (WHO), about 422 million people globally have diabetes. Likewise, the number of asthma and chronic obstructive pulmonary disease patients (COPD) is increasing rapidly.

According to the WHO, around 235 million people suffer from asthma. As a result, peak flow meters, which are used to gauge respiration rate, are increasingly used. The market for patient monitoring devices is driven by the simplicity with which it is handled, transported, and remotely accessible. Major market players are engaging in a variety of tactics to expand the industry, including partnerships, cooperation, innovation, launches, and mergers.

During the COVID-19 outbreak, social segregation and quarantining procedures were put into place worldwide. Many people avoided regular hospital visits as a result. Many people now need routine home temperature and oxygen level monitoring to maintain track of their health, thereby demanding monitoring devices at home.

Various government programs are supporting the pandemic outbreak. The FDA has granted Emergency Use Authorizations (EUAs) for a few wearables and patient monitoring devices to improve access to medicines, monitor patients more closely, and lessen the risk of SARS-CoV-2 exposure to medical professionals during the COVID-19 pandemic.

The growing popularity of wearable and remote patient monitoring devices is another factor fueling the market’s expansion. By fusing clinical symptomology with vital indicators, wearable technology helps in the diagnosis of many chronic diseases. Thus, there has been a dramatic rise in the usage of wearable technology to combat COVID-19.

The wearable medical device market is anticipated to reach $174.48 Billion by 2030, expanding at a 27.1% CAGR during the forecast period (2022-2030), according to Market Research Future.

MetAlert identifies the total addressable market for its wearable patient monitoring tech for those with Alzheimer’s, dementia, and autism at more than 34 million potential patients in North America, Europe, South Africa, and Asia.

Management Team

Patrick E. Bertagna is Founder, CEO and Chairman at MetAlert. He began his career in apparel sales in 1983 and was promoted to national sales manager within two years. In 1986, he founded his first company importing apparel from Europe and selling to U.S. retailers from JCPenney to Neiman Marcus. He has founded several technology and apparel companies, including MetAlert in 2002, which he took public in 2008. He attended Cal State University Northridge with a business major and a psychology minor.

Louis Rosenbaum is COO of MetAlert. He co-founded Global Trek Xploration and was an initial investor in MetAlert. He has successfully started companies in multiple industries, including apparel, environmental services, and the music industry, achieving annual revenues in the multi-millions of dollars. He previously was president of Elements, a women’s apparel company, and of Advanced Environmental Services.

Alex McKean is CFO at MetAlert. He is also the CFO of Encore Brands Inc., a position he has held since 2009. He has held positions as Controller and VP of Finance at 24:7 Film and, Director of FP&A/SVP at Franchise Mortgage Acceptance Company, Corporate Accounting Manager/Treasurer of Polygram Filmed Entertainment and Assistant Treasurer/Controller for State Street Bank. He holds an International MBA from Thunderbird School of Global Management and undergraduate degrees in business and political science from Trinity University.

MetAlert Inc. (OTC: MLRT), closed Wednesday's trading session at $0.2149, up 16.8252%, on 9,969 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.06/$1.00.

Recent News

India Globalization Capital Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital Inc. (NYSE American: IGC).

India Globalization Capital (NYSE American: IGC) today announced its receipt of a no objection letter from HealthCanada for approval of its “Phase 2, Multi-Center, Double-Blind,Randomized, Placebo-Controlled Trial of the Safety and Efficacy ofIGC-AD1 on Agitation in Participants with Dementia due toAlzheimer’s Disease.” The letter provides the acknowledgement ofIGC-AD1’s drug candidacy and the authority to proceed with phase 2trials in Canada. “We are pleased to have received this noobjection letter from Health Canada, which allows us to begin phase2 trials on our drug formulation IGC-AD1 at sites throughoutCanada,” said Ram Mukunda, CEO of IGC. “We already have one testingsite signed up in Canada, bringing our total number of sites tothree, and we are currently in negotiations for several more sitesin Florida, Maryland and Montreal. This will also allow us torecruit a diverse population that reflects the demographics of thedisease. Receiving this approval is a milestone in our progresstowards gaining FDA approval and increases the number of patientswith Alzheimer’s that we can enroll. We now have access to severaladditional locations, including the USA, for our team to safely andefficiently test the efficacy of IGC-AD1 for the treatment ofagitation in dementia due to Alzheimer’s disease.”

To view the full press release, visit

India Globalization Capital Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule ( As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products ( such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand ( that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.


IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.


The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

India Globalization Capital Inc. (NYSE American: IGC), closed Wednesday's trading session at $0.3469, up 2.3606%, on 157,230 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.30/$1.16.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

The Minnesota Medical Board has endorsed decriminalization of illicit drugs, low quantity possession expungements and promotion ofharm-reduction projects. Approved this month, the recommendation isto remove criminal sanctions for possessing a negligible amount ofillicit drugs or drug paraphernalia for personal use. The boardalso asked for an administrative panel to be created to providetreatment advice and lawful penalties to petty offenders who arefound in possession of drugs. This dual approach ensures the policyreduces harm, similar to the one at play in Portugal. The boardsaid it is urgent to increase investment for harm reduction andinstallation of programs for the treatment of patients with opioiddisorders. The board also noted that freeing inmates currentlyimprisoned over low amount possession and expungement of a criminalrecord on an inmate were also important. As policies aroundmarijuana ease in different jurisdictions, opportunities willeventually arise for adults to grow their own cannabis indoorsusing innovative equipment such as that manufactured by Advanced Container Technologies Inc. (OTC: ACTX) and other such entities.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.


Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.


ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Wednesday's trading session at $0.4, up 20.8277%, on 200 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2005/$1.42.

Recent News

Cub Crafters Inc.

The QualityStocks Daily Newsletter would like to spotlight Cub Crafters Inc.

CubCrafters, the leading designer and manufacturer of light-sport,experimental and Part 23 certified backcountry aircraft, has beenmodeled around a culture of innovation. This, coupled with thededication and output of its now more than 200 highly skilledpersonnel, has propelled the company to be a leader in its marketsegment. “This status is evidenced by several parameters, includingCubCrafters’ average aircraft revenue per customer, which has grownfrom just over $5 million in 2001 to over $30 million in 2021,according to the company’s Regulation A+ presentation. In fact, thecompany reported resilient sales as well as a growing market sharein 2021 despite pandemic-related supply chain issues,” a recentarticle reads. “As a further testament to this leadership, twoCubCrafters aircraft are the recipients of only a handful of Part23 certificates that the FAA has issued over the last two decades.Moreover, CubCrafters has been among the very few companies toobtain a new type certificate – an approval that signifiescompliance with requirements on airworthiness, design of theaircraft and all component parts, noise, exhaust emissionstandards, and more – in backcountry aviation since 1970.CubCrafters’ distinctiveness has led to demand for its aircraft,leading to the company being fully booked until 2024.”

To view the full article, visit

Cub Crafters Inc. (typically styled CubCrafters) is an OEM aircraft manufacturer based at McAllister Field Airport in Yakima, Washington. The company was founded in 1980 to build parts and supplementary type certificate (STC) improvement modifications, which were used to establish it as the preeminent center for rebuilding the classic Piper PA-18 Super Cub light aircraft. CubCrafters went on to advance the market with its own, newly manufactured aircraft models and holds an approved Federal Aviation Administration (FAA) Production Certificate. Yakima-based operations include an engineering design-test-certification center, aircraft parts and assembly production facilities, and an MRO maintenance service and overhaul facility.

The first newly manufactured aircraft by the company, the CC18-180 Top Cub, was Federal Aviation Administration (FAA) type certified in December 2004. The Top Cub was also granted type certificates (TC) by Transport Canada in July 2008, followed by Australian certification in August of that same year. With the FAA’s release of the new Light Sport Aircraft (LSA) class, CubCrafters created a brand-new model in 2008, the CC11-100 Sport Cub, similarly based on the original Piper J-3 Cub’s appearance, which it validated to ASTM international standards as an LSA. This model advanced to become known as the Carbon Cub, the bestselling LSA of all time in the U.S.

CubCrafters focuses on four main product lines, including the Carbon Cub SS, Carbon Cub FX, XCub, and the Top Cub under license. Some models are built to be lightweight and powerful for quicker flights, while others are built for longer missions in unforgiving backcountry environments.

CubCrafters has a service and overhaul facility for PA-18 Super Cubs and other Cub derivative designs at its Yakima headquarters. The company sells aircraft kits as well as finished aircraft.


The Carbon Cub is available in three variants: Carbon Cub SS (production Light Sport Aircraft), Carbon Cub FX (an innovative Builder Assist E/A-B aircraft) and Carbon Cub EX (E/A-B aircraft kit). Carbon Cub has been designed for off-airport operation with a powerful engine, strong lightweight airframe and nimble low-speed manners. The Carbon Cub has taken the fundamentally superior design of the Piper Super Cub and reinvented it using 21st century materials and computer-aided design. Superior engineering results include the Carbon Cub having 50% fewer parts and weighing more than 300 pounds less than a similarly equipped Super Cub. Now in its third generation of innovation advancements, there are over 1,000 Carbon Cubs flying.

The CubCrafters CC19-180 XCub, FAA Certified and introduced in June 2016, is supplied complete and ready-to-fly. The XCub is a further scaled development of the CubCrafters Carbon Cub, which the company continues to supply, but with higher performance and incorporating more structural carbon fiber. The XCub was developed over a six-year period and not publicly announced until FAA TC had been completed and issued. The process was completed organically using company resources and did not involve any venture capital, loans nor any advanced customer deposits. XCub is built on a wholly original fuselage design. The CNC-milled 4130 chromoly steel frame meets the latest FAA Part 23 certification standards for 2,300-pound gross weight aircraft. XCub’s useful load is as high as 1,084 pounds. Current Part 23 certification requirements ensure this is the strongest Cub ever produced. It can fly farther, providing greater comfort. It is an airplane that has taken the best from the past and, using the very latest in design, material and manufacturing technology, has established a new standard.

The XCub was approved by the FAA for seaplane operations in December 2017. That same month, EASA approved the XCub design and issued a new type certificate. Four international type certificates have been gained: EASA Dec-2017, Canada Feb-2018, Japan April-2018, and Australia Aug-2018.

CubCrafters increased the horsepower of the XCub line in 2019, offering two new models: the CC19-215 FAA Certified version and the CCX-2300 Builder Assist, both powered by the new CC393i 215 HP engine built by Lycoming.

In December 2021, CubCrafters gained FAA Certification of a new nose wheel version of the XCub, branded the NXCub.

Market Overview

According to a 2022 analysis by research firm Expert Market Research (“EMR”), the global ultralight and light aircraft market was valued at $7.63 billion in 2021. The EMR report says the market is expected to grow at a CAGR of 4.5% in the forecast period of 2022-2027 to reach a value of $9.93 billion. Ultralight and light aircraft are small aircraft with on-board pilot (and perhaps passengers) designed for use in recreation, sports, pilot training, aerial surveys, mapping, research and agriculture, humanitarian backcountry access, and special military missions, as well as business and personal travel.

CubCrafters currently enjoys a dominant market share of the rugged adventure airplane market.

Management Team

Patrick Horgan is President and CEO at CubCrafters. Before he assumed that role, he was the company’s Vice President/Director of Engineering & Product Development for three years, when he led the FAA Part 23 type certificate approval and production certificate approval of CubCrafters’ newest flagship, the XCub. Mr. Horgan also directed the breakthrough certification that authorized the use of experimental avionics in FAA-certified production aircraft, a first in aviation history. He brings over 30 years’ aircraft development and manufacturing experience in general aviation, commercial, and military industries. Prior to service at the company, he was the General Manager at WACO Classic Aircraft Corporation in Battle Creek, Michigan, and was the commercial aircraft manager of the Boeing 777 wheel and brake program for Goodrich Aerospace in Troy, Ohio. He was also a designer on the F/A-18 Super Hornet at McDonnell Douglas (now Boeing) in St. Louis, Missouri. Mr. Horgan holds degrees in aeronautical and astronautical engineering from the University of Illinois, and a certificate in Disruptive Strategy from Harvard Business School. He serves as a member of the Board of Directors of the General Aviation Manufacturers Association and on ASTM aircraft standards committees.

Brad Damm is Vice President at CubCrafters. He has overseen CubCrafters’ sales, marketing, and brand management operations since 2018. Since first joining CubCrafters in 2013, Mr. Damm has served as Factory Direct Sales Manager, the Director of Sales Support, the Global Director of Sales, and the Vice President of Sales and Marketing. During his tenure, the company has seen new sales records year after year across all of CubCrafters new aircraft and kit product lines, and the CubCrafters brand has risen to new levels of awareness and respect with aviation consumers worldwide. Prior to joining the company, he served for over 10 years as the Business Development Manager for one of the largest commercial concrete contractors in the Pacific Northwest, driving the sales and revenue growth that allowed the company to expand from a few dozen to hundreds of employees.

Rick Johnson is the Director of Finance at CubCrafters and has been with the company since 2017. He has 27 years of previous experience as controller and CFO for fruit packing and timber operations in the Pacific Northwest. He holds a Bachelor of Science in Business Administration from Central Washington University.

Christopher Matus is Production Manager at CubCrafters and joined the company in 2011. Before taking that post, he held positions as Fabrication Plant Manager, Machine Shop Manager and CNC Machinist for the company. He has also served as a Combat Engineer in the Washington Army National Guard, deploying to Afghanistan and to natural disasters including the 2014 Oso Mudslide.

Justin Jansky is the Administrative Manager at CubCrafters. He joined the company in 2015 and has a demonstrated history of successful collaboration on major FAA type certification projects in the general aviation industry, specifically under 14 CFR Parts 21 and 23. He is responsible for process management, document control, facilitating FAA certification processes, coordination with FAA delegates and documenting compliance testing. He holds a bachelor’s degree in technology and applied design.

Recent News


GeoSolar Technologies Inc.

The QualityStocks Daily Newsletter would like to spotlight GeoSolar Technologies Inc.

Representative Ed Perlmutter, who sponsored the Secure and FairEnforcement Banking (SAFE) legislation, has retired from Congress. The congressman recently filed the text of his banking measure asan amendment to a large-scale appropriations bill. Senate Majority Leader ChuckSchumer had worked with the congressman to draft the Safe PLUSpackage. However, opposition from Senate Minority Leader Mitch McConnell and other Republicans madeit hard for the amendments to be included in the National DefenseAuthorization Act. Senator Cory Booker also assigned blame toMcConnell, noting that his opposition to marijuana reform had influenced Republican members who would have otherwise been open to approving the spending billcontaining SAFE banking language. The recent amendment containedprovisions to a pair of separate initiatives on gun rights formarijuana consumers and expungement of previous cannabisconvictions. As one, the amendments made up a SAFE Plus compromise,which advocates expected would be included in the appropriationsbill; the measure was still not approved. The failure to passlegislation allowing cannabis banking is a setback for theindustry, but the existence of alternative funding sources offeredby companies such as REZYFi Inc. provide a stop gap to access funds for expansion and normaloperations.

GeoSolar Technologies Inc. (“GST”) is a Colorado-based climate technology company and the creator of the Smart Green Home® system for newly built and existing residences and commercial buildings. The company is focused on revolutionizing the way we heat, cool and power homes with 100% natural energy sources. Its patent-pending integrated system harnesses energy from the earth and sun to power and purify homes and automobiles without the use of fossil fuels.

In a GST home, the sun’s energy is captured on the roof to generate all of the electricity required. Additionally, the consistent climate of the earth is used to keep the home at a perfect temperature year-round, and the company’s proprietary air purifying unit ensures that the air inside the home is safe and healthy.

GST’s home technology has been installed in multiple test homes in Colorado and achieved exceptional results, including some of the most impressive energy efficiency ratings (HERS) in the industry.

GeoSolar Technologies is currently accepting investment as part of a Regulation A+ offering. Everyone* can invest now for as little as $300. For more information, visit the company’s profile on Manhattan Street Capital and review its Offering Circular.

GeoSolar Technologies Inc. (“GST”) has been qualified by the U.S. Securities and Exchange Commission (SEC) to conduct a Regulation A+ capital raise. GST is already a publicly traded company who makes quarterly and annual filings with the SEC and is subject to quarterly PCAOB audits. This is the first time shares of GeoSolar Technologies are being made available for public purchase. Upon completion of this Regulation A+ offering, the company intends to seek a listing of its stock.


The Decarbonization Movement

Soaring and unstable energy/fuel costs continue to highlight the importance of rethinking the traditional approach to powering homes, from top to bottom. While most everyone is well aware of the remarkable, multi-trillion-dollar opportunity the electric vehicle transformation offers to investors (in addition to the benefits to the climate problem), few recognize that the all-electric home market is as large as electric vehicles and equally important to reducing carbon emissions.

U.S. energy expenditures clocked in at $3,891 per person in 2018, leading to estimated spending of $1.3 trillion on energy that year alone. Despite this, fewer than 3% of U.S. homes are currently powered by solar. This number is poised to increase exponentially as both new and existing residences transition to zero carbon models.

GST estimates that if all the homes in America were powered by its technology, carbon pollution could be reduced by an estimated 1.9 trillion pounds per year, greatly reducing the negative impacts on our climate.


The GeoSolarPlus (“GSP”) system combines solar power, geothermal ground-sourced energy and other clean energy technologies into one fully integrated system.
Key benefits of the GSP system include:

  • Making a real planet-changing difference in reducing air pollution
  • Eliminating or significantly reducing homeowners’ future utility bills
  • Enjoying lifetime energy independence and protection from price escalation and energy shortages
  • Eliminating greenhouse gas emissions from operation of home and daily life
  • Increasing home value
  • An integrated design for seamless operation of renewable energy systems
  • Maintaining a significantly healthier living environment
  • Leveraging existing renewable energy tax credits and electrification incentives
  • Creating stable jobs capable of supporting families in the decarbonized future

Click here to learn more about how GeoSolarPlus works.

Management Team

The GST leadership and management team includes some of the world’s most experienced and respected leaders in the fields of decarbonization and sustainable homes.

Stone Douglass is the Chairman and CEO of GST. He is a seasoned, 30-year public company executive and former Chairman and CEO of the Piper Aircraft Company.

Brent Mosbarger is the company’s Co-Founder and leads its commercial operations. He is a highly respected solar engineer whose experience includes roles with Chevron Energy’s green operations and serving as project manager and executive for a $400 million solar/geothermal innovation project.

Peter Romenesko is a Senior Strategic Advisor with GST. He brings to the company considerable experience as an engineer and large-scale project manager for Johnson Controls and Siemens.

Dr. Norbert Klebl is the company’s Co-Founder and Development Director. Recognized as one of the world’s leading experts in the field of zero-carbon innovation, he is a former McKinsey partner of 16 years with an MBA from Columbia.

Dar-Lon Chang is GST’s Director of New Product Development. Prior to joining GST, he had a 16-year career with ExxonMobil Energy Research. He received his PhD in engineering from the University of Illinois.

* Must be over 18, certain states are not currently available and will be added soon.

Recent News


REZYFi, Inc.

The QualityStocks Daily Newsletter would like to spotlight REZYFi, Inc.

• Natural gas prices quadrupled over the last two years

• Electrification presented as solution to rising energy costs,global warming, and fossil fuel dependence

• Inflation Reduction Act of 2022 helps ease transition with rebatesand tax credits for heat pumps

• GeoSolar’s SmartGreen(TM) Home system offers a total-home makeover,including geothermal-powered heat pump, solar panels, upgrades toinsulation, windows, and lighting systems

Natural gas prices have quadrupled over the last two years ( Upward pressure on prices coupled with government incentives areleading consumers to seek electric-based solutions to heat andpower their homes. GeoSolar Technologies (“GST”), a climate technology company based in Colorado, helpshomeowners fully maximize the shift to electrification with theirSmartGreen(TM) whole-home renewable energy systems that leverageelectric power while lowering bills, reducing carbon emissions, andproviding unparalleled energy efficiency.

REZYFi, Inc. is a cannabis mortgage bank servicing the needs of both traditional and non-traditional consumers and businesses. Its target markets include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financings, such as solar installations and real estate development projects.

Headquartered in Miami, Florida, REZYFi operates through two wholly owned subsidiaries – REZYFi Lending, which primarily addresses emerging real estate-related financing opportunities, and ResMac Inc., the company’s traditional mortgage origination, correspondent and servicing operation. REZYFi is currently licensed in 34 U.S. states, with plans to expand to all remaining states later this year.

REZYFi is positioned as one of first cannabis mortgage bankers in the U.S., while most traditional lenders are still reticent to serve the state-licensed cannabis industry.


REZYFi Lending

REZYFi Lending leverages a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans and adjustable-rate mortgages.

Looking ahead, the company expects increased funding in marketing and loan agents to drive significant origination growth over the next two years, further supported by the planned launch of a high-margin cannabis division later this year.

ResMac Inc.

ResMac has been in operation for 13 years, having closed more than 20,000 loans for more than 15,000 clients. The company expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination for the same period. ResMac is further targeting $600 million in origination through its mortgage correspondent operations for 2023.

Through its ResMac subsidiary, REZYFi operates as a direct lender and originator of residential mortgages, with active mortgage correspondent and mortgage servicing operations. Through its correspondent segment, ResMac primarily purchases and aggregates residential mortgages from trusted third-party originators.

The company intends to harvest the database of customers within its mortgage servicing operations as an essential source of additional growth, especially relative to the new alternative residential loan programs being offered.

Corporate Strengths

  • Experience – REZYFi is led by a seasoned management team with significant expertise spanning a wide range of real estate and financing subsectors. The team also has extensive experience in the cannabis and hemp marketplace, which the company intends to leverage as it navigates the changing landscape of the cannabis industry while sourcing the best opportunities in the sector.
  • Network of Independent Brokers – Over the past five years, REZYFi has developed an extensive network of independent mortgage-related brokers and licensed loan officers. The company is currently training the network members on its new service offerings, with many already launching sales efforts. REZYFi believes this network will be a vital asset moving forward as other firms in the sector terminate relationships in the face of slowing mortgage business in a rising interest rate environment.
  • Proprietary Technology – REZYFi has invested heavily in designing, building and implementing proprietary automated/machine learning technology to shorten loan processing timeframes and increase efficiencies, allowing it to operate its legacy business at staffing levels meaningfully below those of its competitors.

Market Overview

REZYFi’s diversified approach to the real estate lending sector positions it to capitalize on growth in multiple verticals in the years to come.

In the first quarter of 2022, lenders issued 2.71 million residential loans, with the average balance for a first mortgage climbing to a record high of $298,324 in 2021, according to the Mortgage Bankers Association. This trend is expected to continue, with Freddie Mac forecasting a 10.4 percent increase in home prices in 2022 and a 5.0 percent bump in 2023. Growth prospects in the cannabis industry paint a similar picture.

The National Association of Realtors® issued a report in April 2021 examining the correlation between cannabis legalization and real estate demand. In states where prescription and recreational cannabis use is legal, more than a third of surveyed agents reported an increase in demand for warehouses. Likewise, 23 percent of those surveyed reported an increase in demand for storefronts, and 28 percent observed increased demand for land. As other states look to join the 19 that have embraced full cannabis legalization, this rising demand could create an opportunity for REZYFi’s cannabis-focused initiatives.

In total, an analysis by market research firm Business Research Insights projects the global loan servicing market to reach a value of nearly $1.5 billion by 2028, up from $680.8 million in 2021. Those figures represent a CAGR of 11.0 percent during the forecast period of 2022-2028.

Management Team

John Vu, Esq., is CEO of REZYFi, Inc. He has more than two decades of experience in the mortgage and commercial banking industry. He has filled many senior and executive management positions in high-producing mortgage banks, including C-level assignments. He has also served as general counsel for a nationally associated commercial bank. Mr. Vu brings considerable cannabis industry expertise to REZYFi. He has served as a corporate attorney to multiple cannabis cultivators, manufacturers and retailers.

Ji Ji Zhang, Esq., is CFO of REZYFi, Inc. He is a multifaceted entrepreneur who owns a law firm, a portfolio of hotels and a high-producing mortgage bank. Mr. Zhang is also an investor in the development of a cannabis business park. He brings more than five years of experience in mortgage banking to REZYFi, having developed Freddie Mac and HUD licenses and amassed a managed portfolio valued at over $300 million.

Kevin Heckemeyer is President of REZYFi, Inc. He has more than 25 years of experience in mortgage banking. He has built and sold several high producing mortgage businesses. In his current roles with ResMac, he is responsible for production and operations.

Spencer Dang is Chief Credit Officer of REZYFi, Inc. He has more than a decade of experience in mortgage operations. He is a direct endorsement underwriter for HUD and has specialized in non-QM underwriting. Under his watch as an underwriter, he has never had a single repurchase.

Recent News


QSAM Biosciences Inc. (OTCQB: QSAM)

The QualityStocks Daily Newsletter would like to spotlight QSAM Biosciences Inc. (OTCQB: QSAM).

Lung cancer is the deadliest type of cancer in the United States,causing more than 100,000 deaths annually, which is more casualties than other kinds of cancers combined. Current lung-cancer treatments include chemotherapy, surgery,targeted therapy, radiation therapy or a combination of theseapproaches. Treatment can be up to 90% effective if the cancer is still small and in early stages, but successrates drop as the tumor becomes larger and more advanced. As therisk of cancer in people under age 50 has increased dramatically, scientists across the country have dedicated their time andenergy to discovering even more efficient cancer therapies.Researchers from the Columbia University School of Engineering and Applied Science have now developed a therapeutic strategy that combinespharmaceutical drugs and bacterial therapies to increase treatmenteffectiveness. The scientists revealed that they have developed apreclinical evaluation pipeline that allowed them to combinebacterial therapies with other types of treatments to boosttreatment efficacy without adding any toxicity. There’s plenty ofongoing research aimed at finding better treatments for variouscancers, and as enterprises such as QSAM Biosciences Inc. (OTCQB: QSAM) make headway in their R&D programs, patients can look forwardto a future where many treatment options exist, hopefully withoutthe numerous side effects current pharmaceuticals are known tohave.

QSAM Biosciences Inc. (OTCQB: QSAM) is a clinical stage biotechnology company focused on bringing to market targeted therapeutic radiopharmaceuticals. The company is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients.

QSAM Biosciences was founded in 2020 by Executive Chairman Dr. C. Richard Piazza and CEO Douglas Baum. It is headquartered in Austin, Texas.


CycloSam®, QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical invented by world-renowned scientists at IsoTherapeutics Group LLC. By leveraging a patented, low specific activity form of Samarium-153 (resulting in far less undesirable europium impurity) and what management believes to be a superior chelating agent in DOTMP, CycloSam is designed to selectively target sites of high bone mineral turnover to deliver a prescribed tumor-killing dose of radiation to the bone tumor sites while minimizing radiation exposure to nearby healthy tissue. These parameters are currently being tested in an FDA-cleared clinical trial.

CycloSam® has been shown in laboratory testing to cause significantly less (30x less) buildup of long-lived radionuclidic impurities than prior FDA-approved drugs, which management believes will enable the ability to safely administer therapeutic doses via higher and multiple-dose regimens and effectively expand its potential clinical utility to therapeutic uses in areas of high unmet medical needs.

The indications for CycloSam® currently being evaluated by QSAM Biosciences include:

  • Metastatic Bone Cancers – On April 28, 2022, QSAM Biosciences announced that the first patient had commenced treatment in its clinical trial evaluating CycloSam in patients with metastatic bone cancer. As noted in the release, the study is a Phase 1 open-label, dose-escalation trial to evaluate the safety, tolerability, dosimetry, and preliminary efficacy of CycloSam®.
  • Pediatric Osteosarcoma/Ewing’s Sarcoma – On February 2, 2022, the company announced that the U.S. FDA has granted Rare Pediatric Disease Designation to CycloSam for the treatment of osteosarcoma. Combined with a previously granted orphan drug designation for osteosarcoma received in 2021, this milestone “may allow QSAM to potentially bring CycloSam® to market more rapidly through additional incentives and eligibilities,” according to CEO Douglas Baum.
  • Bone Marrow Ablation – In a 2020 single patient Investigational New Drug (IND) study, an investigator concluded that high-dose CycloSam® can be administered safely to ablate bone marrow in advance of a stem cell transplant with no apparent renal toxicity and no unexpected adverse events attributable to the drug.

QSAM Biosciences’ preclinical and clinical development pipeline is supported by a strong IP portfolio. The company has secured 14 patents across three distinct patent families spanning the U.S., Japan, Canada and the European Union.

Market Outlook

Through its ongoing development of CycloSam®, QSAM Biosciences is targeting multiple large and underserved market opportunities. According to the American Cancer Society, roughly 400,000 new cases of malignant bone metastasis are diagnosed annually in the U.S. alone. Additionally, QSAM will pursue indications for osteosarcoma and Ewing’s sarcoma that are the most common primary malignancies of bone tissues in children.

Despite this pressing need, the current standard of care for bone cancer is aggressive and suboptimal, leading to marginal success with significant side effects and poor long-term survival prognosis. As a result, QSAM Biosciences estimates a sizable market opportunity for its development pipeline.

  • Bone Metastasis has an estimated total addressable market of $20 billion in the U.S. based on total new cases and comparable drug pricing.
  • Osteosarcoma/Ewing’s Sarcoma have a total addressable market of roughly $125 million in the U.S. based on approximately 1,000 new cases in 2021.
  • The total addressable market for Bone Marrow Ablation is projected at $1 billion, with an estimated 32,000 procedures completed annually.

The company anticipates that the ability to administer CycloSam® for higher and multiple-dose regimens may expand its clinical utility for therapeutic uses in additional areas of high unmet medical needs.

Management Team

QSAM Biosciences is led by an experienced management team and board with an extensive record of FDA approvals, big pharma partnerships and M&A transactions.

Dr. C. Richard Piazza is the Executive Chairman of QSAM Biosciences. Since 2017, he has also served as President and CEO of IGL Pharma Inc., the licensor of CycloSam®, and as a consultant to IsoTherapeutics Group LLC, the inventors of the technology. Dr. Piazza also currently serves on the board of directors of NovaScan LLC, a privately held cancer detection and diagnostics company. He has more than 48 years of health care experience in both medical devices and pharmaceutical/biotech and has led several technology companies to market success, including numerous FDA approvals in both sectors. Dr. Piazza obtained a BS in Economics and a BS in Speech Pathology from the State University of New York and an MA & PhD in Economics from the University of Buffalo and Leeds University.

Douglas R. Baum is the company’s CEO and Director. He brings to QSAM Biosciences over 30 years of experience in the bioscience and biotech industries, including development, FDA/EMA approval and commercialization of multiple drugs and medical devices. Mr. Baum has overseen 15 product approvals through the FDA and EMA and raised over $85 million in capital to fund breakthrough technologies. From 2017 to 2020, he consulted with multiple medical schools and biotech and pharmaceutical companies, and, from 2012 to 2017, he served as President, Chief Executive Officer and Director of Xeris Pharmaceuticals Inc. Mr. Baum holds a Master of Science in Technology Commercialization and a BBA in International Business and Marketing from the University of Texas.

Adam King is the CFO of QSAM Biosciences. He is also the Founder and CEO of King Consulting Group, where he provides a range of financial and reporting services for clients. Before founding King Consulting Group in January 2021, Mr. King was the CFO for Netsertive, a venture-backed digital marketing company. From 2016 to 2018, he was the Office Managing Audit Director for BDO’s Greenville, South Carolina, office, in addition to serving as Audit Director in Raleigh, North Carolina, and Boston, Massachusetts. While at BDO, Mr. King worked with various clients, from tech and life science start-ups to billion-dollar publicly traded companies. He holds a Bachelor of Science in Accounting from Elon University and is a CPA in Raleigh, North Carolina.

QSAM Biosciences Inc. (OTCQB: QSAM), closed Wednesday's trading session at $4.99, even for the day, on 100 volume. The average volume for the last 3 months is 100 and the stock's 52-week low/high is $3.50/$14.00.

Recent News

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

BiondVax has released statistically significant results showingefficacy of its inhaled NanoAb as anti-COVID-19 therapy, as part ofa preclinical proof-of-concept animal study

The study was conducted in collaboration with the world-renownedinstitutes Fraunhofer Institute for Toxicology and ExperimentalMedicine (“ITEM”) and The University of Veterinary MedicineHannover (“TiHo”)

The technology is exclusively licensed from the prestigious MaxPlanck Institute for Multidisciplinary Sciences and the UniversityMedical Center Gottingen

CEO Amir Reichman is scheduled to present in person at the BiotechShowcase (San Francisco – January 9th during JPM Healthcareconference week) and the BIO CEO & Investor Conference (NewYork – February 6th)

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on the development,manufacturing, and commercialization of innovativeimmunotherapeutic products used primarily for the treatment ofinfectious and autoimmune diseases, recently released keyfinancials for the quarter ending September 30, 2022, andhighlighted important business updates (

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Wednesday's trading session at $2.98, off by 0.957192%, on 48,644 volume. The average volume for the last 3 months is 46,386 and the stock's 52-week low/high is $2.80/$23.10.

Recent News

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF).

Psychedelic therapies are poised to revolutionize the psychiatricindustry. With America’s mental health crisis getting worse by the year, researchers have been casting their attention on psychedelics fortheir potential mental-health benefits. Initial research intohallucinogenic drugs such as psilocybin and ketamine has revealedthat they are capable of alleviating the symptoms of a variety ofmental illnesses. As a result, pharmaceutical companies have beeninjecting millions of dollars into psychedelic research and the development of psychedelic-assisted therapies.Experts predict that the market for psychedelic drugs will growexplosively over the next decade, increasing from around $2 billionin 2020 to $10.75 billion by 2027.The enthusiasm being directed at getting trained in overseeingpsychedelic-assisted therapy means that as companies such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) expand their footprint in different jurisdictions, there will beno shortage of qualified personnel to take up any positions createdby the expansion.

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

  • Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
  • Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
  • Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
  • Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

  • 32 million people in the U.S. have used psychedelics at least once
  • 17% of all American adults between 21 and 64 have used psychedelics at least once
  • $500 billion is spent in the U.S. every year on prescription drugs
  • $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
  • The anxiety disorder and depression treatment market is estimated at $16 billion
  • $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Corp. (DELCF), closed Wednesday's trading session at $0.0372, off by 3.125%, on 606 volume. The average volume for the last 3 months is 606 and the stock's 52-week low/high is $0.022/$0.123.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.